- Publish date:
Nplate® Approved for ITP
Nplate® Approved for ITP
Nplate® Approved for ITP
Amgen’s platelet simulator Nplate® (romiplostim) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic immune thrombocytopenic purpura (ITP) who are refractory to standard therapy.
As an approval requirement, the FDA has ordered a Risk Evaluation and Mitigation Strategy (REMS) to assess post-marketing risks and benefits. To monitor long-term safety of Nplate, REMS includes a Medication Guide requiring all prescribers and patients to enroll in a registry.
What Should Women Know About Bladder Cancer
Michael O’Donnell, MD Director of Urologic Oncology, University of Iowa Hospitals and Clinics
Liquid Biopsy Detects Disease Progression Much Earlier Than Imaging
What if a simple blood test could quickly determine when chemotherapy was ineffective and prevent its unnecessary use?
